The latest medical news on transthyretin amyloidosis
Online version
ATTR Expert
Tuesday July 08, 2025
ATTR Expert
Hello     ,
Below, you will find the latest scientific news regarding transthyretin amyloidosis, sourced from the most prestigious peer-reviewed journals.
News

Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study
Orphanet Journal of Rare Diseases 2025; 20(1): 95 |  Péréon Yann et al.
Chronic inflammatory demyelinating-like polyradiculoneuropathy (CIDP) is an autoimmune disease of the peripheral nervous system affecting myelin. CIDP is rare, with a reported prevalence ranging from 0.15...
READ MORE +

Complete Remission after Patisiran Treatment in a Patient with Nephrotic Syndrome Secondary to Hereditary Transthyretin Amyloidosis (ATTR)
Amyloid, March, 1–4. |  Vila et al.
We present the case of a 63-year-old woman patient with renal biopsy-proven ATTRv (hereditary transthyretin amyloidosis) and nephrotic syndrome presentation treated with patisiran after unsatisfactory...
READ MORE +

Associations between pathophysiological traits and symptom development in retrospective analysis of V30M and V122I transthyretin amyloidosis
International journal of cardiology. Heart & vasculature 2025; 58(In progress): 101663 |  Kini, Sameer U. et al.
The Val30Met (V30M) and Val122Ile (V122I) transthyretin (TTR) mutations often beget hereditary amyloid transthyretin amyloidosis (hATTR). Since symptoms are progressively debilitating and potentially fatal...
READ MORE +
Bibliographic data :  News  |  Archives  |  Highlight  |  My bibliography
Useful links:  Homepage  |  Bibliographic research
GNM Healthcare
Copyright 2025 © GNM Healthcare Consulting France SAS
With the institutional support of Alnylam Pharmaceuticals
Inform/Invite a colleague  | My account  | Delete my data
By requesting access to the "ATTR Expert" service, I agree that GNM Healthcare Consulting France SAS may use the data acquired during my access request to provide me with twice per month information related to its services in accordance with the Privacy Policy.
You have the right to access, rectify and delete your data, which you can exercise by sending your request to dpo@gnmhealthcare.com. You can exercise your right to object by requesting the deletion of your data at any time by clicking on the "Delete my data" link.